Smaller CpG-Conjugated Gold Nanoconstructs Achieve Higher Targeting Specificity of Immune Activation
Source abstract
Abstract
This study describes a side-by-side comparison of the in vitro immunostimulatory activity of cytosine-phosphate-guanine (CpG)-conjugated gold nanoparticles. Three different gold nanoparticle cores (13 nm spheres, 50 nm spheres, and 40 nm stars) with the same CpG surface density were investigated for toll-like receptor 9 activation. For this parameter set, 13 nm spheres displayed significantly higher specificity for targeting immune receptors and larger nanoparticles (50 nm spheres and 40 nm stars) showed higher cellular uptake and higher immune activation because of off-target effects. Changes in nanoparticle size and presentation of activating ligands affect construct-induced immune responses at different levels, and care must be taken when considering practical and global design rules for CpG delivery.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immune cells in cancer · Immunotherapy and Immune Responses · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (47)
Show source-provided references
1. 10.1093/intimm/dxh18610.1093/intimm/dxh186 ↗
2. 10.1016/j.jaci.2005.05.03610.1016/j.jaci.2005.05.036 ↗
3. 10.1111/j.1600-065X.2007.00572.x10.1111/j.1600-065X.2007.00572.x ↗
4. 10.1084/jem.2003016210.1084/jem.20030162 ↗
5. 10.1073/pnas.16129349810.1073/pnas.161293498 ↗
6. 10.1038/3504712310.1038/35047123 ↗
7. 10.1038/nrd205910.1038/nrd2059 ↗
8. 10.1586/erv.10.17410.1586/erv.10.174 ↗
9. 10.1016/S0167-4781(99)00140-210.1016/S0167-4781(99)00140-2 ↗
10. 10.1021/nl802958f10.1021/nl802958f ↗
11. 10.1126/science.112555910.1126/science.1125559 ↗
12. 10.1073/pnas.130580411010.1073/pnas.1305804110 ↗
13. 10.1038/mt.2014.3010.1038/mt.2014.30 ↗
14. 10.1007/s11095-006-9180-510.1007/s11095-006-9180-5 ↗
15. 10.1021/acsnano.5b0771610.1021/acsnano.5b07716 ↗
16. 10.1002/adfm.20130234710.1002/adfm.201302347 ↗
17. 10.1002/smll.20130090310.1002/smll.201300903 ↗
18. 10.1021/nn305700510.1021/nn3057005 ↗
19. 10.1371/journal.pone.006355010.1371/journal.pone.0063550 ↗
20. 10.1002/anie.20110518710.1002/anie.201105187 ↗
21. 10.1073/pnas.150285011210.1073/pnas.1502850112 ↗
22. 10.1016/j.celrep.2016.12.07310.1016/j.celrep.2016.12.073 ↗
23. 10.1021/acsnano.5b0513810.1021/acsnano.5b05138 ↗
24. 10.1021/nn300296p10.1021/nn300296p ↗
25. 10.1038/cmi.2012.3810.1038/cmi.2012.38 ↗
26. 10.1186/ar146910.1186/ar1469 ↗
27. 10.1126/science.109362010.1126/science.1093620 ↗
28. 10.1126/science.109361610.1126/science.1093616 ↗
29. 10.4049/jimmunol.090259210.4049/jimmunol.0902592 ↗
30. 10.1021/nl500844m10.1021/nl500844m ↗
31. 10.1021/acs.bioconjchem.7b0025210.1021/acs.bioconjchem.7b00252 ↗
32. 10.1038/nnano.2011.19110.1038/nnano.2011.191 ↗
33. 10.2147/IJN.S2659210.2147/IJN.S26592 ↗
34. 10.1186/s12951-014-0045-510.1186/s12951-014-0045-5 ↗
35. 10.1016/j.smim.2003.10.00910.1016/j.smim.2003.10.009 ↗
36. Decker T. · Blood · 2000 · 95 · 99910.1182/blood.V95.3.999.003k10_999_1006 ↗
37. 10.1073/pnas.95.21.1263110.1073/pnas.95.21.12631 ↗
38. 10.1002/1521-4141(200205)32:5<1212::AID-IMMU1212>3.0.CO;2-D10.1002/1521-4141(200205)32:5<1212::AID-IMMU1212>3.0.CO;2-D ↗
39. 10.1074/jbc.M60531120010.1074/jbc.M605311200 ↗
40. 10.1136/ard.60.90003.iii4310.1136/ard.60.90003.iii43 ↗
41. 10.3389/fimmu.2014.0049110.3389/fimmu.2014.00491 ↗
42. 10.3791/408410.3791/4084 ↗
43. 10.1378/chest.118.2.50310.1378/chest.118.2.503 ↗
44. 10.1177/1045441195006002010110.1177/10454411950060020101 ↗
45. 10.1155/2012/49080410.1155/2012/490804 ↗
46. 10.1186/1556-276X-6-44010.1186/1556-276X-6-440 ↗
47. 10.1021/acs.chemmater.6b0324210.1021/acs.chemmater.6b03242 ↗